866-997-4948(US-Canada Toll Free)

CytomX Therapeutics, Inc. - Product Pipeline Review - 2014

Published By :

Global Markets Direct

Published Date : Dec 2014

Category :

Pharmaceutical

No. of Pages : 30 Pages

CytomX Therapeutics, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Directs, CytomX Therapeutics, Inc. - Product Pipeline Review - 2014, provides an overview of the CytomX Therapeutics, Inc.s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CytomX Therapeutics, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of CytomX Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CytomX Therapeutics, Inc.s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the CytomX Therapeutics, Inc.s pipeline products

Reasons to buy

- Evaluate CytomX Therapeutics, Inc.s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CytomX Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CytomX Therapeutics, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CytomX Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CytomX Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of CytomX Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
CytomX Therapeutics, Inc. Snapshot 5
CytomX Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
CytomX Therapeutics, Inc.- Research and Development Overview 6
Key Therapeutic Areas 6
CytomX Therapeutics, Inc.- Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products- Monotherapy 9
Pipeline Products- Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
CytomX Therapeutics, Inc.- Pipeline Products Glance 12
CytomX Therapeutics, Inc.- Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
CytomX Therapeutics, Inc.- Drug Profiles 14
CTX-023 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
CTX-033 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
CTX-1003 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Monoclonal Antibody Conjugated for Cancer 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Monoclonal Antibodies for Cancer 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Monoclonal Antibody Conjugated for Oncology 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Monoclonal Antibody to Antagonize Interleukin-6 Receptor for Inflammation 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Monoclonal Antibody to Inhibit Glycoprotein-130 for Inflammation 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Monoclonal Antibody to Target Notch Pathway for Cancer 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CytomX Therapeutics, Inc.- Pipeline Analysis 23
CytomX Therapeutics, Inc.- Pipeline Products by Target 23
CytomX Therapeutics, Inc.- Pipeline Products by Molecule Type 24
CytomX Therapeutics, Inc.- Pipeline Products by Mechanism of Action 25
CytomX Therapeutics, Inc.- Recent Pipeline Updates 26
CytomX Therapeutics, Inc.- Dormant Projects 27
CytomX Therapeutics, Inc.- Locations And Subsidiaries 28
Head Office 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30

List of Tables
CytomX Therapeutics, Inc., Key Information 5
CytomX Therapeutics, Inc., Key Facts 5
CytomX Therapeutics, Inc.- Pipeline by Indication, 2014 7
CytomX Therapeutics, Inc.- Pipeline by Stage of Development, 2014 8
CytomX Therapeutics, Inc.- Monotherapy Products in Pipeline, 2014 9
CytomX Therapeutics, Inc.- Partnered Products in Pipeline, 2014 10
CytomX Therapeutics, Inc.- Partnered Products/ Combination Treatment Modalities, 2014 11
CytomX Therapeutics, Inc.- Preclinical, 2014 12
CytomX Therapeutics, Inc.- Discovery, 2014 13
CytomX Therapeutics, Inc.- Pipeline by Target, 2014 23
CytomX Therapeutics, Inc.- Pipeline by Molecule Type, 2014 24
CytomX Therapeutics, Inc.- Pipeline Products by Mechanism of Action, 2014 25
CytomX Therapeutics, Inc.- Recent Pipeline Updates, 2014 26
CytomX Therapeutics, Inc.- Dormant Developmental Projects,2014 27

List of Figures
CytomX Therapeutics, Inc. - Pipeline by Top 10 Indication, 2014 7
CytomX Therapeutics, Inc. - Pipeline by Stage of Development, 2014 8
CytomX Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 9
CytomX Therapeutics, Inc. - Pipeline by Top 10 Target, 2014 23
CytomX Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2014 24
CytomX Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 25

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *